Loading...

PE anti-human CD69 Antibody PE anti-human CD69 Antibody

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50
PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 PE
  • FN50
    PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
310905 25 tests DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310906 100 tests DKK850
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD69 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kongsomboonvech AK, et al. 2020. PLoS Pathog. 16:e1008327. PubMed
  2. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  3. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  4. Claeys E, et al. 2021. Front Immunol. 12:650731. PubMed
  5. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed
  8. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  9. Blake D, et al. 2022. Elife. 11:. PubMed
  10. Ainsua-Enrich E, et al. 2022. iScience. 25:105455. PubMed
  11. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  12. Chen J, et al. 2023. Cell Res. 33:341. PubMed
  13. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  14. Yuan X, et al. 2023. Oncoimmunology. 12:2219544. PubMed
  15. Wang F, et al. 2023. Sci Adv. 9:eadf5464. PubMed
  16. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
  17. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  18. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  19. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  20. Kieffer T, et al. 2017. J Reprod Immunol. 10.1016/j.jri.2016.11.004. PubMed
  21. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  22. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  23. Magalhães L, et al. 2015. PLoS Negl Trop Dis. 10: 0003816. PubMed
  24. Fiaux PC, et al. 2020. PLoS Comput Biol. 16:e1008194. PubMed
  25. Schmitz T, et al. 2021. J Reprod Immunol. 148:103424. PubMed
  26. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
  27. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  28. Park S, et al. 2015. J Biol Chem. 290: 17349 - 17366. PubMed
  29. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  30. Gardner TJ, et al. 2022. Nat Chem Biol. 18:216. PubMed
  31. Oikawa D, et al. 2020. Front Immunol. 11:601926. PubMed
  32. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  33. Frensch M, et al. 2021. Cell Mol Life Sci. 78:8165. PubMed
  34. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  35. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  36. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  37. Jaudszus A, et al. 2013. J Lipid Res. 54:923. PubMed
  38. Arvindam US, et al. 2021. Leukemia. 35:1586. PubMed
  39. Aschmoneit N, et al. 2022. Oncoimmunology. 11:2028961. PubMed
  40. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  41. Zhou Y, et al. 2016. J Leukoc Biol. 100: 1201 - 1211. PubMed
  42. Laroni A, et al. 2016. J Autoimmun. 72:8-18. PubMed
  43. Aschmoneit N, et al. 2021. Sci Rep. 11:13880. PubMed
  44. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  45. Costantini C, et al. 2010. Int Immunol. 1.490972222. PubMed
  46. Liu Y, et al. 2022. MAbs. 14:2073632. PubMed
  47. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  48. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  49. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  50. Zhang P, et al. 2021. Nat Med. 22:. PubMed
  51. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  52. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  53. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
  54. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  55. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
  56. Su S, et al. 2016. Sci Rep. 6:20070. PubMed
  57. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  58. Cohen Z, et al. 2020. Biomed Rep. 13:17. PubMed
  59. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  60. Zimmermann M, et al. 2019. Front Immunol. 10:829. PubMed
  61. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
  62. Wang R, et al. 2016. Proc Natl Acad Sci U S A. 113: 11501 - 11506. PubMed
  63. Guenther C, et al. 2019. Front Immunol. 10:1138. PubMed
  64. Hoseini SS, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
  65. Shan L, et al. 2017. Immunity. 47:766. PubMed
  66. Kongsomboonvech AK, et al. 2020. PLoS Pathog. 16:e1008327. PubMed
  67. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  68. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  69. Claeys E, et al. 2021. Front Immunol. 12:650731. PubMed
  70. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  71. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  72. Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed
  73. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  74. Blake D, et al. 2022. Elife. 11:. PubMed
  75. Ainsua-Enrich E, et al. 2022. iScience. 25:105455. PubMed
  76. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  77. Chen J, et al. 2023. Cell Res. 33:341. PubMed
  78. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  79. Yuan X, et al. 2023. Oncoimmunology. 12:2219544. PubMed
  80. Wang F, et al. 2023. Sci Adv. 9:eadf5464. PubMed
  81. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
  82. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  83. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  84. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  85. Kieffer T, et al. 2017. J Reprod Immunol. 10.1016/j.jri.2016.11.004. PubMed
  86. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  87. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  88. Magalhães L, et al. 2015. PLoS Negl Trop Dis. 10: 0003816. PubMed
  89. Fiaux PC, et al. 2020. PLoS Comput Biol. 16:e1008194. PubMed
  90. Schmitz T, et al. 2021. J Reprod Immunol. 148:103424. PubMed
  91. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
  92. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  93. Park S, et al. 2015. J Biol Chem. 290: 17349 - 17366. PubMed
  94. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  95. Gardner TJ, et al. 2022. Nat Chem Biol. 18:216. PubMed
  96. Oikawa D, et al. 2020. Front Immunol. 11:601926. PubMed
  97. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  98. Frensch M, et al. 2021. Cell Mol Life Sci. 78:8165. PubMed
  99. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  100. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  101. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  102. Jaudszus A, et al. 2013. J Lipid Res. 54:923. PubMed
  103. Arvindam US, et al. 2021. Leukemia. 35:1586. PubMed
  104. Aschmoneit N, et al. 2022. Oncoimmunology. 11:2028961. PubMed
  105. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  106. Zhou Y, et al. 2016. J Leukoc Biol. 100: 1201 - 1211. PubMed
  107. Laroni A, et al. 2016. J Autoimmun. 72:8-18. PubMed
  108. Aschmoneit N, et al. 2021. Sci Rep. 11:13880. PubMed
  109. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  110. Costantini C, et al. 2010. Int Immunol. 1.490972222. PubMed
  111. Liu Y, et al. 2022. MAbs. 14:2073632. PubMed
  112. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  113. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  114. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  115. Zhang P, et al. 2021. Nat Med. 22:. PubMed
  116. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  117. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  118. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
  119. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  120. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
  121. Su S, et al. 2016. Sci Rep. 6:20070. PubMed
  122. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  123. Cohen Z, et al. 2020. Biomed Rep. 13:17. PubMed
  124. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  125. Zimmermann M, et al. 2019. Front Immunol. 10:829. PubMed
  126. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
  127. Wang R, et al. 2016. Proc Natl Acad Sci U S A. 113: 11501 - 11506. PubMed
  128. Guenther C, et al. 2019. Front Immunol. 10:1138. PubMed
  129. Hoseini SS, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
  130. Shan L, et al. 2017. Immunity. 47:766. PubMed
RRID
AB_314840 (BioLegend Cat. No. 310905)
AB_314841 (BioLegend Cat. No. 310906)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine5 anti-human CD69 FN50 FC
Purified anti-human CD69 FN50 FC,CyTOF®,IHC-F
FITC anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
APC anti-human CD69 FN50 FC
APC/Cyanine7 anti-human CD69 FN50 FC
PE/Cyanine7 anti-human CD69 FN50 FC
PE/Dazzle™ 594 anti-human CD69 FN50 FC
Brilliant Violet 711™ anti-human CD69 FN50 FC
APC/Fire™ 750 anti-human CD69 FN50 FC
TotalSeq™-A0146 anti-human CD69 FN50 PG
TotalSeq™-B0146 anti-human CD69 FN50 PG
TotalSeq™-C0146 anti-human CD69 FN50 PG
Brilliant Violet 750™ anti-human CD69 FN50 FC
KIRAVIA Blue 520™ anti-human CD69 FN50 FC
Spark NIR™ 685 anti-human CD69 Antibody FN50 FC
PE/Fire™ 640 anti-human CD69 FN50 FC
Alexa Fluor® 700 anti-human CD69 FN50 FC
Alexa Fluor® 488 anti-human CD69 FN50 FC
Alexa Fluor® 647 anti-human CD69 FN50 FC,SB
Pacific Blue™ anti-human CD69 FN50 FC
Biotin anti-human CD69 FN50 FC
PerCP/Cyanine5.5 anti-human CD69 FN50 FC
PerCP anti-human CD69 FN50 FC
Brilliant Violet 421™ anti-human CD69 FN50 FC
Brilliant Violet 785™ anti-human CD69 FN50 FC
Brilliant Violet 510™ anti-human CD69 FN50 FC
Brilliant Violet 650™ anti-human CD69 FN50 FC
Brilliant Violet 605™ anti-human CD69 FN50 FC
Purified anti-human CD69 (Maxpar® Ready) FN50 FC,CyTOF®
Spark YG™ 581 anti-human CD69 FN50 FC
TotalSeq™-D0146 anti-human CD69 FN50 PG
Spark Blue™ 550 anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
APC anti-human CD69 FN50 FC
Spark Red™ 718 anti-human CD69 FN50 FC
PE/Fire™ 810 anti-human CD69 FN50 FC
GMP PE anti-human CD69 FN50 FC
PE/Fire™ 744 anti-human CD69 FN50 FC
Spark PLUS UV395™ anti-human CD69 FN50 FC
Spark Blue™ 574 anti-human CD69 (Flexi-Fluor™) FN50 FC
GMP APC anti-human CD69 FN50 FC
Spark YG™ 593 anti-human CD69 (Flexi-Fluor™) Antibody FN50 FC
Spark UV™ 387 anti-human CD69 (Flexi-Fluor™) FN50 FC
PerCP/Fire™ 806 anti-human CD69 Antibody FN50 FC
Brilliant Violet 570™ anti-human CD69 FN50 FC
StarBright UltraViolet 740 anti-human CD69 FN50 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50
PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 PE
  • FN50
    PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
310905 25 tests DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310906 100 tests DKK850
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD69 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kongsomboonvech AK, et al. 2020. PLoS Pathog. 16:e1008327. PubMed
  2. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  3. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  4. Claeys E, et al. 2021. Front Immunol. 12:650731. PubMed
  5. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed
  8. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  9. Blake D, et al. 2022. Elife. 11:. PubMed
  10. Ainsua-Enrich E, et al. 2022. iScience. 25:105455. PubMed
  11. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  12. Chen J, et al. 2023. Cell Res. 33:341. PubMed
  13. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  14. Yuan X, et al. 2023. Oncoimmunology. 12:2219544. PubMed
  15. Wang F, et al. 2023. Sci Adv. 9:eadf5464. PubMed
  16. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
  17. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  18. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  19. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  20. Kieffer T, et al. 2017. J Reprod Immunol. 10.1016/j.jri.2016.11.004. PubMed
  21. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  22. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  23. Magalhães L, et al. 2015. PLoS Negl Trop Dis. 10: 0003816. PubMed
  24. Fiaux PC, et al. 2020. PLoS Comput Biol. 16:e1008194. PubMed
  25. Schmitz T, et al. 2021. J Reprod Immunol. 148:103424. PubMed
  26. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
  27. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  28. Park S, et al. 2015. J Biol Chem. 290: 17349 - 17366. PubMed
  29. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  30. Gardner TJ, et al. 2022. Nat Chem Biol. 18:216. PubMed
  31. Oikawa D, et al. 2020. Front Immunol. 11:601926. PubMed
  32. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  33. Frensch M, et al. 2021. Cell Mol Life Sci. 78:8165. PubMed
  34. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  35. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  36. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  37. Jaudszus A, et al. 2013. J Lipid Res. 54:923. PubMed
  38. Arvindam US, et al. 2021. Leukemia. 35:1586. PubMed
  39. Aschmoneit N, et al. 2022. Oncoimmunology. 11:2028961. PubMed
  40. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  41. Zhou Y, et al. 2016. J Leukoc Biol. 100: 1201 - 1211. PubMed
  42. Laroni A, et al. 2016. J Autoimmun. 72:8-18. PubMed
  43. Aschmoneit N, et al. 2021. Sci Rep. 11:13880. PubMed
  44. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  45. Costantini C, et al. 2010. Int Immunol. 1.490972222. PubMed
  46. Liu Y, et al. 2022. MAbs. 14:2073632. PubMed
  47. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  48. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  49. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  50. Zhang P, et al. 2021. Nat Med. 22:. PubMed
  51. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  52. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  53. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
  54. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  55. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
  56. Su S, et al. 2016. Sci Rep. 6:20070. PubMed
  57. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  58. Cohen Z, et al. 2020. Biomed Rep. 13:17. PubMed
  59. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  60. Zimmermann M, et al. 2019. Front Immunol. 10:829. PubMed
  61. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
  62. Wang R, et al. 2016. Proc Natl Acad Sci U S A. 113: 11501 - 11506. PubMed
  63. Guenther C, et al. 2019. Front Immunol. 10:1138. PubMed
  64. Hoseini SS, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
  65. Shan L, et al. 2017. Immunity. 47:766. PubMed
  66. Kongsomboonvech AK, et al. 2020. PLoS Pathog. 16:e1008327. PubMed
  67. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  68. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  69. Claeys E, et al. 2021. Front Immunol. 12:650731. PubMed
  70. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  71. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  72. Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed
  73. Jaiswal A, et al. 2022. Cancer Cell. 40:524. PubMed
  74. Blake D, et al. 2022. Elife. 11:. PubMed
  75. Ainsua-Enrich E, et al. 2022. iScience. 25:105455. PubMed
  76. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  77. Chen J, et al. 2023. Cell Res. 33:341. PubMed
  78. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  79. Yuan X, et al. 2023. Oncoimmunology. 12:2219544. PubMed
  80. Wang F, et al. 2023. Sci Adv. 9:eadf5464. PubMed
  81. Marquardt I, et al. 2022. Front Microbiol. 12:752549. PubMed
  82. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  83. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  84. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  85. Kieffer T, et al. 2017. J Reprod Immunol. 10.1016/j.jri.2016.11.004. PubMed
  86. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  87. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  88. Magalhães L, et al. 2015. PLoS Negl Trop Dis. 10: 0003816. PubMed
  89. Fiaux PC, et al. 2020. PLoS Comput Biol. 16:e1008194. PubMed
  90. Schmitz T, et al. 2021. J Reprod Immunol. 148:103424. PubMed
  91. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
  92. Bellini N, et al. 2022. iScience. 25:105234. PubMed
  93. Park S, et al. 2015. J Biol Chem. 290: 17349 - 17366. PubMed
  94. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  95. Gardner TJ, et al. 2022. Nat Chem Biol. 18:216. PubMed
  96. Oikawa D, et al. 2020. Front Immunol. 11:601926. PubMed
  97. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  98. Frensch M, et al. 2021. Cell Mol Life Sci. 78:8165. PubMed
  99. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  100. Sibener LV et al. 2018. Cell. 174(3):672-687 . PubMed
  101. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  102. Jaudszus A, et al. 2013. J Lipid Res. 54:923. PubMed
  103. Arvindam US, et al. 2021. Leukemia. 35:1586. PubMed
  104. Aschmoneit N, et al. 2022. Oncoimmunology. 11:2028961. PubMed
  105. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  106. Zhou Y, et al. 2016. J Leukoc Biol. 100: 1201 - 1211. PubMed
  107. Laroni A, et al. 2016. J Autoimmun. 72:8-18. PubMed
  108. Aschmoneit N, et al. 2021. Sci Rep. 11:13880. PubMed
  109. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  110. Costantini C, et al. 2010. Int Immunol. 1.490972222. PubMed
  111. Liu Y, et al. 2022. MAbs. 14:2073632. PubMed
  112. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  113. Halkias J, et al. 2019. J Clin Invest. 130:3562. PubMed
  114. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  115. Zhang P, et al. 2021. Nat Med. 22:. PubMed
  116. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  117. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  118. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
  119. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  120. Tao L, et al. 2020. Cancers (Basel). 12:00. PubMed
  121. Su S, et al. 2016. Sci Rep. 6:20070. PubMed
  122. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  123. Cohen Z, et al. 2020. Biomed Rep. 13:17. PubMed
  124. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  125. Zimmermann M, et al. 2019. Front Immunol. 10:829. PubMed
  126. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
  127. Wang R, et al. 2016. Proc Natl Acad Sci U S A. 113: 11501 - 11506. PubMed
  128. Guenther C, et al. 2019. Front Immunol. 10:1138. PubMed
  129. Hoseini SS, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
  130. Shan L, et al. 2017. Immunity. 47:766. PubMed
RRID
AB_314840 (BioLegend Cat. No. 310905)
AB_314841 (BioLegend Cat. No. 310906)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine5 anti-human CD69 FN50 FC
Purified anti-human CD69 FN50 FC,CyTOF®,IHC-F
FITC anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
APC anti-human CD69 FN50 FC
APC/Cyanine7 anti-human CD69 FN50 FC
PE/Cyanine7 anti-human CD69 FN50 FC
PE/Dazzle™ 594 anti-human CD69 FN50 FC
Brilliant Violet 711™ anti-human CD69 FN50 FC
APC/Fire™ 750 anti-human CD69 FN50 FC
TotalSeq™-A0146 anti-human CD69 FN50 PG
TotalSeq™-B0146 anti-human CD69 FN50 PG
TotalSeq™-C0146 anti-human CD69 FN50 PG
Brilliant Violet 750™ anti-human CD69 FN50 FC
KIRAVIA Blue 520™ anti-human CD69 FN50 FC
Spark NIR™ 685 anti-human CD69 Antibody FN50 FC
PE/Fire™ 640 anti-human CD69 FN50 FC
Alexa Fluor® 700 anti-human CD69 FN50 FC
Alexa Fluor® 488 anti-human CD69 FN50 FC
Alexa Fluor® 647 anti-human CD69 FN50 FC,SB
Pacific Blue™ anti-human CD69 FN50 FC
Biotin anti-human CD69 FN50 FC
PerCP/Cyanine5.5 anti-human CD69 FN50 FC
PerCP anti-human CD69 FN50 FC
Brilliant Violet 421™ anti-human CD69 FN50 FC
Brilliant Violet 785™ anti-human CD69 FN50 FC
Brilliant Violet 510™ anti-human CD69 FN50 FC
Brilliant Violet 650™ anti-human CD69 FN50 FC
Brilliant Violet 605™ anti-human CD69 FN50 FC
Purified anti-human CD69 (Maxpar® Ready) FN50 FC,CyTOF®
Spark YG™ 581 anti-human CD69 FN50 FC
TotalSeq™-D0146 anti-human CD69 FN50 PG
Spark Blue™ 550 anti-human CD69 FN50 FC
PE anti-human CD69 FN50 FC
APC anti-human CD69 FN50 FC
Spark Red™ 718 anti-human CD69 FN50 FC
PE/Fire™ 810 anti-human CD69 FN50 FC
GMP PE anti-human CD69 FN50 FC
PE/Fire™ 744 anti-human CD69 FN50 FC
Spark PLUS UV395™ anti-human CD69 FN50 FC
Spark Blue™ 574 anti-human CD69 (Flexi-Fluor™) FN50 FC
GMP APC anti-human CD69 FN50 FC
Spark YG™ 593 anti-human CD69 (Flexi-Fluor™) Antibody FN50 FC
Spark UV™ 387 anti-human CD69 (Flexi-Fluor™) FN50 FC
PerCP/Fire™ 806 anti-human CD69 Antibody FN50 FC
Brilliant Violet 570™ anti-human CD69 FN50 FC
StarBright UltraViolet 740 anti-human CD69 FN50 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account